Moderna filing with FDA for Omicron adapted COVID vaccine 'imminent' - Bloomberg
Maddie Meyer         

Moderna (NASDAQ:MRNA) is very close to filing data with the US FDA as part of an Emergency Use Authorization (EUA) for an updated COVID-19 vaccine that contains protection against Omicron subvariants, Bloomberg reported.
The filing will include preclinical data of the bivalent vaccine against the BA.4 and BA.5 Omicron subvariants, currently the dominant strains in the US, the news service said. It will also include clinical data from another bivalent vaccine that targets the initial Omicron strain.
On Monday, Pfizer (PFE) and BioNTech (BNTX) submitted EUA application for their revamped COVID vaccine to the FDA.